Large cap global equity portfolio that offers above-average dividend income and defensive characteristics.
In a global investment landscape that features scarcity of income yield in public equities, Global Equity Income aims to generate sustainable and above-average dividend income streams via investments in high quality global companies.
The portfolio is composed of large-cap defensive equities with a heavy tilt towards defensive sectors such as Healthcare and Communication Services. As such, Global Equity Income features lower sensitivity (low beta) to the broad global equity indices and its low volatility profile enables strong downside protection. Non-U.S. equities account for 60% of the portfolio.
Portfolio construction is based on quantitative scoring of our global equity universe with a focus on Value, Quality, Safety, Payout, Technical and Sentiment metrics, as well as ESG traits. In particular, the Quality and Safety metrics ensure that stock selection is geared towards low-risk companies that exhibit high levels of profitability and low financial leverage.
|Asset Class||Weight (%)|
|1. Merck & Co Inc||5.51%|
|2. Bristol-Myers Squibb Co||5.28%|
|3. Gilead Sciences Inc||4.74%|
|4. AbbVie Inc||4.68%|
|5. Takeda Pharmaceutical Co Ltd||3.96%|
|6. Omnicom Group Inc||3.95%|
|7. Novartis AG||3.93%|
|8. Unilever PLC||3.92%|
|9. AT&T Inc||3.92%|
|10. E.ON SE||3.83%|